Sociedad Americana de Hirudoterapia

Clinical Outcomes of Anticoagulated Patients With Atrial Fibrillation After Falls or Head Injury: Insights From RE-LY.

Randomized controlled trial published in Stroke (2023)

Última actualización: 18 de junio de 2026Revisado por: ASH Editorial Board
Artículo de investigación — revisión de evidenciaReferencia del artículo
Evidence: Randomized controlled trialEnsayos clínicosDesarrollo de fármacosCaldeira et al. · Stroke, 2023

Abstract

BACKGROUND: Falls are always a concern regarding the balance of risk/benefit in patients with atrial fibrillation treated with anticoagulants. In this analysis, we aimed to evaluate the outcomes of patients that had a fall/head injury reported in the RE-LY clinical trial (Randomized Evaluation of Long-Term Anticoagulation Therapy) and to explore the safety of dabigatran (a nonvitamin K antagonist oral anticoagulant). METHODS: We performed a post hoc retrospective analysis of intracranial hemorrhage and major bleeding outcomes in the RE-LY trial with 18 113 individuals with atrial fibrillation, according to the status occurrence of falls (or head injury) reported as adverse events. Multivariate Cox regression models were used to provide adjusted hazard ratio (HR) and 95% CI. RESULTS: In the study, 974 falls or head injury events were reported among 716 patients (4%). These patients were older and had more frequently comorbidities such as diabetes, previous stroke, or coronary artery disease. Patients with fall had a higher risk of major bleeding (HR, 2.41 [95% CI, 1.90-3.05]), intracranial hemorrhage (HR, 1.69 [95% CI, 1.35-2.13]), and mortality (HR, 3.91 [95% CI, 2.51-6.10]) compared to those who did not have reported falls or head injury. Among patients who had falls, those allocated to dabigatran showed a lower intracranial hemorrhage risk (HR, 0.42 [95% CI, 0.18-0.98]) compared with warfarin. CONCLUSIONS: In this population, the risk of falls is important and confers a worse prognosis, increasing intracranial hemorrhage, and major bleeding. Patients who fell and were under dabigatran was associated with lower intracranial hemorrhage risk than those anticoagulated with warfarin, but the analysis was merely exploratory.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeRandomized Controlled TrialJournal Article
Indexed MeSH termsHumansWarfarinAtrial FibrillationDabigatranAccidental FallsRetrospective StudiesAnticoagulantsStrokeHemorrhageIntracranial HemorrhagesCraniocerebral Trauma

Resumen

Falls are always a concern regarding the balance of risk/benefit in patients with atrial fibrillation treated with anticoagulants. In this analysis, we aimed to evaluate the outcomes of patients that had a fall/head injury reported in the RE-LY clinical trial (Randomized Evaluation of Long-Term...

Por qué esto importa para la hirudoterapia

Este análisis retrospectivo post hoc del ensayo RE-LY evaluó los desenlaces entre 716 pacientes con fibrilación auricular que sufrieron caídas o traumatismo craneoencefálico mientras estaban anticoagulados, encontrando que las caídas confirieron riesgos significativamente mayores de sangrado mayor (HR 2.41), hemorragia intracraneal (HR 1.69) y mortalidad (HR 3.91) en comparación con pacientes sin caídas. Entre los pacientes que sufrieron caídas, aquellos con dabigatrán mostraron menor riesgo de hemorragia intracraneal que aquellos con warfarina (HR 0.42), aunque el análisis fue descrito como meramente exploratorio. El resumen no menciona sanguijuelas, hirudoterapia, hirudina ni ninguna terapia derivada de la sanguijuela. Su relevancia para ASH es inexistente, ya que el estudio compara dos anticoagulantes orales convencionales sin ninguna conexión con intervenciones basadas en sanguijuelas o con el secretoma de la sanguijuela.

Citación

Clinical Outcomes of Anticoagulated Patients With Atrial Fibrillation After Falls or Head Injury: Insights From RE-LY.

Caldeira et al. · Stroke, 2023

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: 18 de junio de 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.